NTRK1 and thyroid gland undifferentiated (anaplastic) carcinoma: First-generation tropomyosin receptor kinase (TRK) inhibitors, larotrectinib and entrectinib, are ATP-competitive inhibitors that bind specifically effective in the treatment of various cancers, including infantile fibrosarcoma [48], anaplastic thyroid cancer [49].